Published in Lab Law Weekly, August 17th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Avalon Pharmaceuticals, Inc.
Report 1: Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX), announced continued positive interim results from its Phase I study of AVN944, for the treatment of hematologic malignancies in elderly and refractory patients. Interim data indicate AVN944 is well tolerated, has dose-dependent pharmacokinetics, induces biomarkers of programmed cell death in cancer cells from patients, and demonstrates stabilized disease in almost half of the patients after...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly